Outcomes of non-ablative and reduced conditioning regimens for chronic myelogenous leukemia (CML) at M.D. Anderson Cancer Center.
| Parameter . | Flag-Ida . | Fludarabine/Melphalan . |
|---|---|---|
| Number | 10 | 33 |
| Donor cell engraftment | 8 | 32 |
| Graft failure | 2 | 2 |
| Relapse | 6 | 8 |
| GVHD ≥ 2 | 1 | 14 |
| Responses after relapse | 2 | 1 |
| 2-yr survival | CP1:80% | CP1:63% |
| Other:20% | Other:33% | |
| 2-yr DFS | CP1:40% | CP1:63% |
| Other:0% | Other:30% |
| Parameter . | Flag-Ida . | Fludarabine/Melphalan . |
|---|---|---|
| Number | 10 | 33 |
| Donor cell engraftment | 8 | 32 |
| Graft failure | 2 | 2 |
| Relapse | 6 | 8 |
| GVHD ≥ 2 | 1 | 14 |
| Responses after relapse | 2 | 1 |
| 2-yr survival | CP1:80% | CP1:63% |
| Other:20% | Other:33% | |
| 2-yr DFS | CP1:40% | CP1:63% |
| Other:0% | Other:30% |